94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1520968
This article is part of the Research Topic Vaccines and Breakthrough Infections View all articles
Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine
Provisionally accepted- 1 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
- 2 Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States
- 3 Institute for Vaccine Safety, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States
Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to lifethreatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.
Keywords: Dengue, ADE, mRNA vaccine, DENV vaccine, tropical disease, vaccine development
Received: 31 Oct 2024; Accepted: 12 Feb 2025.
Copyright: © 2025 Liu and Salmon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Daniel A Salmon, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.